ACNT ASCENT INDUSTRIES CO.
Chemicals & Allied Products · Nasdaq · SEC CIK 95953 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY22.4%
TTM net income YoY-207.7%
TTM EPS YoY-211.1%
Revenue 3-yr CAGR-23.9%
Net income 3-yr CAGR—
Margins
Gross margin20.8%
Operating margin-2.7%
Net margin-1.0%
FCF margin-8.7%
EBITDA margin-1.3%
Returns
ROE-1.1%
ROA-0.8%
ROIC (approx.)-4.8%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets24.6%
Debt / equity0.00x
Current ratio4.50x
Interest coverage—
Cash quality & payout
Operating cash flow / net income5.48x
Accruals ratio3.7%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $74.94M | $80.76M |
| Cost of revenue | $57.73M | $70.07M |
| Gross profit | $17.21M | $10.69M |
| R&D expense | $71,000 | $0 |
| SG&A expense | $22.96M | $19.86M |
| Operating income | -$7.03M | -$10.80M |
| Interest expense | — | $418,000 |
| Pretax income | -$5.56M | -$10.77M |
| Income tax | $22,000 | $1.81M |
| Net income | $867,000 | -$13.60M |
| EBITDA | -$5.89M | -$9.76M |
| EPS (basic) | 0.09 | -1.35 |
| EPS (diluted) | 0.09 | -1.35 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 9.64M | 10.11M |
| Balance sheet | ||
| Cash & equivalents | $57.61M | $16.11M |
| Receivables | $10.04M | $12.23M |
| Inventory | $8.74M | $5.73M |
| Current assets | $83.02M | $83.07M |
| PP&E, net | $15.76M | $17.59M |
| Goodwill | $0 | $0 |
| Intangibles | $2.83M | $3.44M |
| Total assets | $111.94M | $147.25M |
| Current liabilities | $12.36M | $22.35M |
| Long-term debt | — | $0 |
| Total debt | — | $0 |
| Total liabilities | $24.95M | $53.70M |
| Shareholders' equity | $86.99M | $93.55M |
| Net debt | — | -$16.11M |
| Shares outstanding | 9.40M | 10.07M |
| Cash flow statement | ||
| Operating cash flow | -$519,000 | $14.68M |
| Capital expenditure | $1.54M | $1.12M |
| Free cash flow | -$2.06M | $13.56M |
| Investing cash flow | $50.98M | $905,000 |
| Financing cash flow | -$8.96M | -$1.33M |
| Depreciation & amortization | $1.13M | $1.04M |
| Stock-based compensation | $1.30M | $760,000 |
| Share buybacks | $9.14M | $1.04M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.